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DOI 10.1016/j.ccr.2010.04.024SUMMARYAcute leukemias induced by MLL chimeric oncoproteins are among the subset of cancers distinguished by
a paradoxical dependence on GSK-3 kinase activity for sustained proliferation. We demonstrate here that
GSK-3 maintains the MLL leukemia stem cell transcriptional program by promoting the conditional associa-
tion of CREB and its coactivators TORC and CBP with homedomain protein MEIS1, a critical component of
the MLL-subordinate program, which in turn facilitates HOX-mediated transcription and transformation. This
mechanism also applies to hematopoietic cells transformed by other HOX genes, including CDX2, which is
highly expressed in a majority of acute myeloid leukemias, thus providing a molecular approach based on
GSK-3 inhibitory strategies to target HOX-associated transcription in a broad spectrum of leukemias.INTRODUCTION
Homeobox (HOX) genes comprise one of the largest groups of
annotated oncogenes (Futreal et al., 2004), and are implicated
in the pathogenesis of various human cancers (Abate-Shen,
2002; Sitwala et al., 2008; Svingen and Tonissen, 2003). They
encode a large and diverse family of transcription factors that
share a conserved 60 amino acid homeodomain DNA-binding
motif. Originally discovered through their causative roles
in homeotic patterning defects, HOX proteins are critical regula-
tors of cell fate, organ and tissue formation, and stem cell func-
tions. In the blood system, HOX proteins regulate hematopoietic
stem cell self-renewal, a process that is perturbed in acute leuke-
mias by either activating mutations ofHOX genes themselves, or
more commonly by mutations or misexpression of their
upstream regulators MLL and CDX2, respectively (Dou and
Hess, 2008; Liedtke and Cleary, 2009; Riedt et al., 2009; Scholl
et al., 2007). Expression of HOXA9 in particular has been linked
with the general prognosis of acute myeloid leukemia (AML).
The HOX regulatory pathway, therefore, constitutes a potentialSignificance
Increasing evidence indicates that inhibition of the GSK-3 mul
and induces the differentiation of a variety of cancers, including
inhibition also stimulates the activities of several oncogenic
mechanisms that dictate its biphasic oncogenic properties. In
the physical and functional association of CREB and its coacti
downstreammediator of the MLL oncogenic program. This in t
HOX-mediated transformation. These findings provide a mol
through GSK-3 inhibition in a subset of leukemias.target for therapeutic interventions in leukemias and other
malignancies.
The DNA-binding and transcriptional properties of HOX
proteins are enhanced by interactions with TALE (three amino
acid loop extension) class homeodomain proteins of the PBX
and MEIS families (Owens and Hawley, 2002; Sitwala et al.,
2008). Genetic studies reveal that TALE proteins are required
for many HOX-dependent developmental and oncogenic pro-
grams. Coexpression of MEIS1 with HOXA9 markedly shortens
the latency for myeloid leukemia in mouse models (Kroon
et al., 1998), and mutations of HOXA9 that prevent interactions
with PBX proteins abrogate its oncogenic properties (Schnabel
et al., 2000). MEIS1 is consistently expressed at high levels in
MLL and CDX2 leukemias, and serves an essential and rate-
limiting role in regulating MLL leukemia stem cell potential
(Rawat et al., 2008; Wong et al., 2007). TALE proteins form
hetero-oligomeric complexes with HOX proteins to recruit
a variety of transcriptional coregulators with either coactivator
or corepressor properties. PKA signaling has been specifi-
cally implicated in the recruitment of coactivators by TALEtifunctional serine/threonine kinase impairs the proliferation
leukemias induced by MLL oncogenes. Conversely, GSK-3
proteins, therefore it is critical to determine the underlying
this report, we demonstrate that GSK-3 activity maintains
vators with MEIS1, a HOX DNA-binding cofactor and critical
urn promotes critical target gene expression responsible for
ecular rationale for targeting HOX-associated transcription
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Figure 1. Global Gene Expression Changes
of MLL Cells in Response to GSK-3 Inhibi-
tion
The data set of gene expression differences
resulting from GSK-3 inhibitor treatment (10 mM
SB216763 for 20 hr) was used for GSEA. Enrich-
ment plots are shown for selected downregulated
gene sets identified by GSEA (Table S2). See also
Tables S1 and S2.
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GSK-3 Promotes MEIS1 and CREB Interactionproteins, and possibly in the interconversion of coregulator
recruitment underlying differential transcriptional activity
(Goh et al., 2009; Huang et al., 2005). Despite these advances,
the signaling pathways that coordinate HOX-TALE transcrip-
tional outputs in normal and neoplastic cells remain largely
undefined.
We have previously shown that glycogen synthase kinase 3
(GSK-3) is required for maintenance of leukemias with MLL
mutations (Wang et al., 2008). GSK-3 is a serine/threonine
kinase that functions on several signaling pathways implicated
in various pathological processes including diabetes, inflamma-
tion, and neurodegenerative disorders (Cohen and Goedert,
2004; De Ferrari and Inestrosa, 2000; Doble and Woodgett,
2003; Martin et al., 2005). In malignancies, inactivating muta-
tions of GSK-3 underscore its normal tumor suppressor
function to downregulate growth-promoting pathways such
as those mediated by WNT, Hedgehog, and MYC proteins
that are inappropriately activated in cancers (Cohen and Goe-
dert, 2004). However, increasing evidence demonstrates that
GSK-3 serves a tumor-promoting role to sustain proliferation
in some cancers, thus opening up the possibility of targeting
GSK-3 for therapeutic purposes (Luo, 2009). Defining the
underlying mechanisms that mediate GSK-3 dependence of598 Cancer Cell 17, 597–608, June 15, 2010 ª2010 Elsevier Inc.specific tumors will provide a molecular
rationale for selective application of
therapies that target GSK-3. In this
report, we investigate how GSK-3 facili-
tates HOX-mediated transcription and
oncogenesis.RESULTS
GSK-3 Maintains the MLL
Leukemia Stem Cell
Transcriptional Program
Gene expression profiling was per-
formed to investigate the mechanisms
underlying MLL leukemia dependence
on GSK-3. Following GSK-3 inhibitor
(SB216763) treatment of the RS4;11
human leukemia cell line, which contains
anMLL-AF4 chromosomal translocation,
1028 differentially expressed genes were
identified, of which 554were upregulated
and 474 downregulated at least 1.5-fold
(see Table S1 available online). Compar-ison of the treatment data set with curated gene sets derived
from diverse published experiments (Subramanian et al., 2005)
revealed that downregulated genes were significantly enriched
for gene sets related to cell cycle (Figure 1), as well as MYC-
regulated and differentiation-associated genes (Table S2),
consistent with growth arrest, decreased MYC expression, and
differentiation changes in MLL myeloid leukemia cells upon
GSK-3 inhibition (Wang et al., 2008).
Genes comprising the MLL leukemia stem cell (LSC) mainte-
nance program, which are shared with embryonic stem cells
as well as poor prognosis human cancers (Somervaille et al.,
2009), were significantly downregulated (Figure 1 and Table
S2), indicating that GSK-3 likely affects MLL LSC potential.
Downregulated genes were also significantly enriched for gene
sets associated with HOX overexpression, including those
induced by coexpression of HOXA9 and MEIS1 (Figure 1), which
are direct MLL transcriptional targets implicated in leukemia
pathogenesis. Furthermore, MYB, a downstream mediator of
HOXA9/MEIS1 in AML (Hess et al., 2006), and its subordinate
transcriptional program, were also downregulated (Table S2).
Thus, GSK-3 inhibition appears to target the LSC program at
or near the apex of the transcriptional hierarchy initiated by
MLL oncoproteins.
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Figure 2. HOX-Induced Proliferation Is Gener-
ally Sensitive to GSK-3 Inhibition
(A) Mouse myeloid progenitors immortalized by
HOXA9 + MEIS1 were cultured in the presence or
absence of 10 mM SB216763. Results show mean
cell numbers expressed as fold-change compared
with day 0 (error bars indicate standard error of the
mean [± SEM], n = 3).
(B) Survival is shown for mice transplanted with
HOXA9/MEIS1 leukemia cells (50,000 cells/mouse)
and maintained on regular chow or chow containing
0.4% lithium with saline water (n = 10 each cohort;
p < 0.01). Acute leukemia was confirmed by peripheral
blood leukocyte counts and/or necropsy.
(C) Western blot analysis (upper panel) was performed
using an anti-GSK-3 antibody on HOXA9/MEIS1
leukemia cells transduced by lentiviral vectors
expressing GSK-3a or GSK-3b shRNAs (#1 or #2 for
each). Migrations of GSK-3 isoforms are indicated.
Bar graph shows the growth of transduced cells in
the presence or absence of 5 mMSB216763 for 3 days.
Results are shown as relative cell proliferation
comparedwith cell numbers in the absence of inhibitor
(error bars indicate ± SEM, n = 3). See also Figure S1.
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GSK-3 Promotes MEIS1 and CREB InteractionThe MLL Subordinate HOX/MEIS Program Sensitizes
Leukemia Cells to GSK-3 Inhibition
Despite downregulation of theMLL LSC transcriptional program,
MLL oncoprotein expression (Wang et al., 2008) and transcrip-
tional activity (Figure S1) were unaffected by GSK-3 inhibition,
prompting an assessment of whether GSK-3 may impact at
the level of HOX and MEIS, which are immediate downstream
effectors of the MLL oncogenic program. Consistent with this
possibility, SB216763 inhibited the proliferation of mouse
myeloid leukemia cells transformed by the combined actions
of HOXA9/MEIS1, which effectively bypass MLL (Figure 2A).
Furthermore, treatment with lithium, a GSK-3 inhibitor, modestly
prolonged the latency for development of AML in transplanted
mice (Figure 2B) similar to the effects of GSK-3 inhibition in
murine models of MLL leukemia (Wang et al., 2008). Physiologic
GSK-3 inactivation using conditional AKT (CA-AKT-ER), which
avoids potential nonspecific effects of chemical GSK-3 inhibi-
tors, induced hyperphosphorylation of GSK-3 and inhibited the
growth of HOXA9/MEIS1 cells (Figure S2). Although knockdown
of GSK-3a or GSK-3b had no adverse effects on cell proliferation
(data not shown), GSK-3b knockdown cells were more sensitive
to SB216763 treatment (Figure 2C). These effects phenocopy
GSK-3 inhibition in MLL leukemia cells, suggesting that GSK-3
may regulate HOX/MEIS rather than MLL oncoprotein activity.GSK-3 Impacts HOX/PBX/MEIS Transcriptional Activity
To further assess the correlation of GSK-3 dependence with
HOX transformation, we examined its role in mouse myeloid
progenitors immortalized by additional homeodomain proteins
HOXB1 and HOXB4, or CDX2, an upstream regulator of HOX
genes (Rawat et al., 2008), and also MEIS1 (Figure S2D), a
HOX DNA-binding cofactor that is necessary (Figure S2E) and
rate limiting (Kroon et al., 1998; Wong et al., 2007) for HOX-asso-
ciated leukemogenesis. When treated with GSK-3 inhibitor,
progenitor proliferation was impaired (Figure 3A) and colony-
forming abilities were dramatically reduced (Figures 3B and3C). Activated AKT, which physiologically inhibits GSK-3, also
decreased cell proliferation, and GSK-3b knockdown increased
sensitivity to GSK-3 inhibitors (Figure S2) phenocopying the
responses of MLL-transformed cells. In contrast, cells trans-
formed by NUP98-HOXA9, an oncogenic HOX protein that aber-
rantly recruits CBP coactivator through the NUP98 moiety, were
unaffected by GSK-3 inhibition (Figures 3B and 3C). Further-
more, cells immortalized by an activated HOX mutant (VP16-
HD-FKBP, which spontaneously dimerizes to activate transcrip-
tion) (Figure S2F) were also insensitive to GSK-3 inhibition
(Figure 3A), and not dependent on MEIS1 for myeloid transfor-
mation (Figure S2E), indicating that mutations conferring consti-
tutive transcriptional effector activity bypass dependence on
GSK-3. These data support a broad role for GSK-3 in HOX-asso-
ciated transformation, and suggest that it may directly impact
HOX/MEIS transcriptional function.
Because HOX-transformed leukemia cells are generally sensi-
tive to GSK-3 inhibition, which downregulates the HOX/MEIS
transcriptional program, we tested whether GSK-3 affects
HOX/MEIS transcriptional activity. Cotransduction of HOXB1
with its cofactors PBX1 and MEIS1 in transient transcription
assays activated expression of a reporter gene under control
of the Hoxb1 autoregulatory element (ARE), as reported
previously (Goh et al., 2009; Jacobs et al., 1999). However, tran-
scriptional activation was abrogated in the presence of GSK-3
inhibitor (Figure 3D), which by contrast had no effect on the abil-
ities of NUP98-HOXA9 or MLL-ENL to activate the HOXA9
promoter (Figure 3E). As expected, GSK-3 inhibition induced
robust expression of the TOP/Flash WNT pathway reporter
gene (Figure 3F). Thus, GSK-3-dependent signaling regulates
HOX/MEIS transcriptional activity.The GSK-3 Dependence of MLL and HOX Transformed
Myeloid Cells Is Modulated by CREB
Gene sets linked with cAMP/CREB activity were also enriched
among the genes downregulated by GSK-3 inhibition in MLLCancer Cell 17, 597–608, June 15, 2010 ª2010 Elsevier Inc. 599
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Figure 3. GSK-3 Regulates HOX/PBX/MEIS Transcription Complex Activity through MEIS1 and CREB Association
(A)Mousemyeloid progenitors immortalized by the indicated geneswere cultured in the presence or absence of 10 mMSB216763. Cell numbers are expressed as
fold-change compared to day 0. Representative experiments are shown (n = 3 each).
(B) Colony-forming ability is shown for myeloid progenitors immortalized by various oncogenes (indicated below) following 5 days culture in the presence or
absence of SB216763. Results are shown relative to mean colony numbers without drug set at 100%.
(C) Colony morphologies are shown for the experiment in (B). The scale bar represents 100 mm.
(D)HoxB1ARE reporter activity was assessed after cotransductionwith constructs encoding the proteins indicated below the panel in the presence or absence of
10 mM SB216763. Luciferase activity was normalized to b-galactosidase activity. Results are shown as fold-change compared with control.
(E and F) Activity of the HOXA9 reporter gene (E) or Top-FlashWNT reporter gene (F) was assessed in the presence or absence of 10 mM SB216763. Results of
a representative experiment are displayed as fold change compared to control. All error bars indicate ± SEM, n = 3. See also Figure S2.
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GSK-3 Promotes MEIS1 and CREB Interactionleukemia cells (Table S2 and Figure 1B). CREB is a transcription
factor involved in various biological processes, including cancer,
whose activity is promoted byGSK-3 phosphorylation (Fiol et al.,
1994; Horike et al., 2008), suggesting that it may play a role in the
GSK-3 dependence of HOX-transformed cells.
Coexpression of CREB with MLL-AF6 revealed a strong
genetic interaction resulting in shortened latency for develop-
ment of leukemia in transplanted mice (Figure 4A), suggesting
that CREB function may be limiting despite misregulation of
HOX/MEIS expression in MLL leukemia. CREB overexpression
also decreased sensitivity to GSK-3 inhibition in cells immortal-
ized by MLL-AF6 or HOXA9/MEIS1 (Figure 4B), whereas CREB
knockdown increased their sensitivity (Figure 4C). Similar effects
were seen in CDX2 immortalized cells where CREB knockdown
reduced proliferation (Figure S3A) and increased sensitivity to
GSK-3 inhibition (Figure S3B). Thus, CREB serves an important
role to modulate the GSK-3 dependence of cells transformed
by misregulation of the HOX pathway.
CREB phosphorylation at Ser133 is essential for its transcrip-
tional activity (Carlezonetal., 2005), andprimessubsequentphos-
phorylationbyGSK-3atSer129 (Fiol et al., 1994),which is required
for expression of several genes (Boer et al., 2008; Horike et al.,
2008; Tyson et al., 2002). Thus, the effects of CREB phosphoryla-600 Cancer Cell 17, 597–608, June 15, 2010 ª2010 Elsevier Inc.tion onMLL and HOX-mediated proliferation were tested. Forced
expression of CREB proteins harboring S129A or S133A mis-
sense mutations displayed dominant-negative effects with
decreased colony forming abilities of MLL and HOXA9/MEIS1
leukemia cells, but not that of cells transformed by E2A-HLF,
which functions independently of the HOX pathway, or NUP98-
HOX9, which is a constitutively active HOX pathway oncoprotein
(Figure 4D). In contrast, forced expression of phosphorylation
mutants for several other GSK-3 downstream targets (b-catenin,
FOXO, and NFAT) did not affect colony-forming abilities (data
not shown). These data suggest that CREB phosphorylation by
GSK-3 is important for MLL and HOX-mediated transformation.
GSK-3 Promotes Conditional MEIS1 Association
with CREB and Its Coactivators to Facilitate
HOX-Mediated Transcription
HOX/MEIS transcriptional activity has been linkedwith the cAMP
signaling pathway, which impinges on CREB (Goh et al., 2009;
Carlezon et al., 2005). Thus, possible physical association of
CREB with the HOX/MEIS complex was assessed by immuno-
precipitation (IP) western blot analysis. Transfected exogenous
CREB in 293T cells and endogenous CREB in AML cells trans-
formed by HOXA9/MEIS1 coprecipitated withMEIS1 (Figure 5A).
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Figure 4. CREB Affects MLL and HOX-Induced Cell Proliferation and Sensitivity to GSK-3 Inhibition
(A) Mouse myeloid progenitors immortalized by MLL-AF6 were transduced with retrovirus expressing CREB or empty vector. Mice (n = 5 each cohort) trans-
planted with the transduced cells were monitored for leukemia-free survival (p < 0.01).
(B) MLL-AF6 or HOXA9/MEIS1 (HM) leukemia cells were stably transduced with CREB (+) or vector (), and then incubated in the presence or absence of 10 mM
SB216763. Cell numbers were enumerated on day 2 and expressed as relative change compared with no SB216763 treatment. Right panel shows protein levels
detected by western blot analysis.
(C) MLL-AF6 or HOXA9/MEIS1 leukemia cells were stably transduced with lentiviral vector expressing CREB shRNAs (#1 or #2) and then incubated in the pres-
ence or absence of 5 mM SB216763. Cell numbers were enumerated on day 2 and displayed as relative change compared to no SB216763 treatment. The right
panel shows CREB protein levels in knockdown cells.
(D) Myeloid progenitors immortalized by the indicated oncogenes were transduced with retroviral vectors expressing the various CREB proteins or empty vector
(). The cells were then plated and colonies enumerated after 5 days culture, and displayed relative to empty vector. Right panel shows CREB protein levels in
transduced cells. HM, HOXA9/MEIS1; MA6, MLL-AF6; EH, E2A-HLF; NA9, NUP98-HOXA9.
All error bars indicate ± SEM of triplicate analyses. See also Figure S3.
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GSK-3 Promotes MEIS1 and CREB InteractionNotably, GSK-3 inhibitor treatment markedly reduced MEIS1-
CREB coimmunoprecipitation (coIP), but not interaction of
MEIS1 with its dimerization partner PBX1b (Figure 5A). Further-
more, GSK3-dependent association of endogenous CREB and
MEIS1 was observed in coprecipitation studies of the human
MLL leukemia cell line MV411 (Figure 5B). Association was not
the result of DNA tethering since nuclease treatment did not
abrogate coprecipitation (data not shown). CREBmutantsS129A
and S133A did not coimmunoprecipitate with MEIS1 (Figure 5C),
further supporting that GSK-3 activity may promote MEIS1-
CREB association. MEIS1 also coprecipitated the CREB coacti-
vators CBP and TORC, which was markedly reduced by GSK-3
inhibition (Figures 5D and 5E). CBP coIP was dependent on the
presence of CREB (Figure 5D), and abrogated in the CREB phos-
phorylation mutants, or by GSK-3 inhibition (Figure 5F), which
reduced S129 phosphorylation to background levels (Figure 5G).
Conversely, CREB-TORC interaction was not abrogated by
GSK-3 inhibition (not shown) consistent with previous studies
(Heinrich et al., 2009), but TORC was necessary for CREB-MEIS
association (Figure 5H) consistent with previous suggestions
that it may directly interact with MEIS1 (Goh et al., 2009; Huang
et al., 2005; Jacobs et al., 1999). Taken together, these results
support GSK-3 facilitated association of the CBP coactivator
complex with MEIS1.The potential impact of GSK-3 on CREB and HOX/MEIS coop-
erative function was assessed in transient transcription assays.
Coexpression of wild-type CREB significantly enhanced tran-
scriptional activation induced by the HOXB1/PBX1/MEIS1
complex on the Hoxb1 ARE (Figure 3D), an authentic MEIS1
target promoter (Goh et al., 2009; Jacobs et al., 1999). Activation
was antagonized by GSK-3 inhibition or coexpression of CREB
phosphorylation mutants. In a heterologous GAL4 system, coex-
pression of CREB or TORC markedly enhanced transcriptional
activation mediated by the MEIS1 C terminus (Figures 5J and
5K), which is implicated in TORC (Goh et al., 2009) and CREB
(Figure 5I) interactions, and was sensitive to GSK-3 inhibition
(Figure 5J). CREB was necessary for TORC enhancement of
MEIS1-mediated transcription (Figure 5L). Thus, GSK-3 activity
promotes the physical and functional association of CREB with
the HOX/PBX/MEIS transcription complex, and higher-order
interactions with CBP and TORC coactivators.
FOS Is a Critical Target Gene of HOX/MEIS and CREB
Responsive to GSK-3 Inhibition
Microarray analysis identified FOS as among the most substan-
tially downregulated genes in response to GSK-3 inhibition in
MLL leukemia cells. Its levels decreased almost 3-fold compared
with much more modest or no decreases of other FOS or JUNCancer Cell 17, 597–608, June 15, 2010 ª2010 Elsevier Inc. 601
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Figure 5. Association of CREB and MEIS1 Is Phosphorylation Dependent
(A) IP-western blot analysis was performed on 293T cells cotransducedwith FLAG-CREB and HA-MEIS1, or AML cells transformed by HOXA9 + HA-MEIS1 in the
presence or absence of 20 mMSB216763. Cell lysates were immunoprecipitated with anti-HA antibody conjugated beads and then analyzed by western blotting
with anti-FLAG (CREB), anti-HA (MEIS1), anti-CREB, or anti-PBX1b antibodies.
(B) Human leukemia cell lines (indicated at the top) were cultured overnight in the presence (+) or absence () of SB216763 (20 mM), and cell lysates were sub-
jected to immunoprecipitation with anti-MEIS monoclonal antibody conjugated beads, then subjected to western blot analysis with rabbit polyclonal antibodies
specific for the indicated endogenous proteins.
(C) HA-MEIS1 was coexpressed with FLAG-tagged CREB proteins (indicated at top) in the presence or absence of 20 mM SB216763. Cell lysates were used for
immunoprecipitation with anti-HA or IgG conjugated beads, then subjected to western blotting with anti-FLAG (CREB) or anti-HA (MEIS1) antibodies.
(D) HA-MEIS1was coexpressedwithCBP,with orwithout FLAG-taggedCREB (indicated at top), in the presenceor absence of 20mMSB216763. Cell lysateswere
used for immunoprecipitationwith anti-HA conjugated beads, then subjected towestern blottingwith anti-CBP, anti-FLAG (CREB), or anti-HA (MEIS1) antibodies.
(E) HA-MEIS1 was coexpressed with FLAG-tagged CREB and V5-tagged TORC1 in the presence or absence of 20 mMSB216763. Cell lysates were immunopre-
cipitated with anti-HA conjugated beads, then subjected to western blotting with anti-V5 (TORC1), anti-FLAG (CREB), or anti-HA (MEIS1) antibodies.
(F) As shown in the left panel, FLAG-tagged CREB (wt or mutant as indicated at top of panel) proteins were expressed in 293T cells, immunoprecipitated with anti-
FLAG antibody conjugated beads, and subjected to western blotting so that the presence of endogenous CBP could be detected. As shown in the right panel,
FLAG-taggedCREBwas expressed in 293Tcells in the absence () or presence (+) of SB216763, immunoprecipitatedwith anti-FLAGantibody conjugatedbeads,
and subjected to western blot analysis for detection of the coprecipitation of endogenous CBP.
(G) FLAG-tagged CREB (or mutant CREB proteins indicated at top of panel) were expressed in 293T cells in the absence () or presence (+) of SB216763 and
immunoprecipitated with anti-FLAG antibody conjugated beads. The precipitate was washed and subjected to western blotting for detection of CREB phosphor-
ylation status with phosphospecific antibodies.
(H) HA-MEIS1 was coexpressed with FLAG-tagged CREB in the presence of TORC2 shRNA constructs (#1, #2). Cell lysates were used for immunoprecipitation
with anti-HA conjugated beads, then subjected to western blotting with anti-TORC2, anti-FLAG (CREB), or anti-HA (MEIS1) antibodies.
(I) HA-MEIS1 (WT) or HA-MEIS1C-terminal deletionmutant (DCT) was coexpressedwith FLAG-taggedCREB. Cell lysates were immunoprecipitatedwith anti-HA
conjugated beads, then subjected to western blotting with anti-FLAG (CREB) or anti-HA (MEIS1) antibodies.
(J) Gal4-MEIS1 CT activity was assessed after cotransduction with CREB or TORC1 in the presence or absence of different GSK-3 inhibitors.
(K) Gal4-MEIS1 CT or mutant reporter activities were assessed after cotransduction with CREB.
(L) Gal4-MEIS1CT reporter activity was assessed following cotransductionwith TORC1orCREBshRNAconstructs (#1, #2) indicated below the panel. Results are
shown as fold-change compared with control.
For (J)–(L), luciferase activity was normalized to b-galactosidase activity. Error bars indicate ± SEM.
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Figure 6. FOS Is a Critical Downstream Effector of HOX/PBX/MEIS and CREB to Mediate GSK-3 Inhibitor Sensitivity
(A) Human MLL-AF4 leukemia cell line RS 4;11 was cultured in the presence or absence of GSK-3 inhibitors (SB216763 or SB415296 for 20 hr). FOS transcripts
were then measured by real-time qPCR, and expressed relative to untreated cells.
(B) Expression of FOS in wild-type (WT) or GSK-3b null (GSK-3b/) cells transformed by E2A-HLF was measured by real-time qPCR and displayed relative to
wild-type cells.
(C) FOS reporter was cotransfected with HOXB1, PBX1b and MEIS1a (H/P/M) or CREB in the presence (+) or absence () of SB216763. Luciferase activity was
normalized with b-galactosidase activity. Results are displayed as fold change compared with control.
(D) Myeloid progenitors immortalized by HOXA/MEIS1 were cultured for 24 hr in the absence () or presence (+) of SB216763. ChIP was performed using anti-
bodies against CREB or HA (MEIS1). Relative occupancy values were normalized against those obtained with IgG.
(E) MLL-AF6 transformedmousemyeloid progenitor cells were stably transduced with a FLAG-FOS construct. Overexpression of FOS is shown by western blot-
ting with anti-FOS antibody. Sensitivities of cells to different concentrations of SB216763 are displayed compared with untreated cells.
(F) MLL-AF6 transformed mouse myeloid progenitors stably transduced with vector () or FOS shRNAs (#1 or #2) and employed for studies in (G) were assessed
for FOS transcript expression by qRT-PCR. Results are displayed relative to vector-transduced cells.
(G) Cells transformed by the indicated oncogenes (top of panels) were transduced with FOS knockdown constructs and cultured in the indicated concentrations
of SB216763. Cell numbers were enumerated and displayed as relative change compared with untreated cells.
All error bars indicate ± SEM of triplicate analyses. See also Figure S4.
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GSK-3 Promotes MEIS1 and CREB Interactionfamily genes (Figure S4A), as confirmed by quantitative poly-
merase chain reaction (qPCR) in cells treated with two different
GSK-3 inhibitors (Figure 6A), and consistent with observations
that GSK-3b deficiency substantially reduces FOS expression
(Figure 6B). Originally identified as a viral oncogene homolog,
FOS is involved in many physiological processes (Curran and
Teich, 1982; Matthews et al., 2007; Ozanne et al., 2007), and is
a known CREB target gene (Gonzales and Bowden, 2002;
Ramirez et al., 1997) whose expression levels have been corre-
lated with HOX expression in various cell types (Krosl and
Sauvageau, 2000; Potter et al., 2006). In transcription assays,expression of a reporter gene under control of the FOS promoter
was induced by CREB or the HOX/PBX/MEIS complex, and was
partially sensitive to GSK-3 inhibition (Figure 6C). Furthermore,
endogenous FOS expression in human leukemia cells was
induced by coexpression of HOXA9 and MEIS1 (Figure S4B).
Conversely, FOS levels were reduced in MEIS1-deficient
immortalized myeloid progenitors (Figure S4C), consistent with
regulation of FOS transcription by the HOX/MEIS/PBX complex.
In HOXA9/MEIS1 transformedmyeloid progenitors, chromatin IP
of the FOS promoter showed MEIS1 and CREB occupancy,
which was reduced by GSK-3 inhibition (Figure 6D).Cancer Cell 17, 597–608, June 15, 2010 ª2010 Elsevier Inc. 603
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Figure 7. Schematic Model Depicting Role of GSK-3 in Promoting
HOX-Mediated Transcription through CREB Phosphorylation
GSK-3 activity promotes conditional association of CREB and its coactivators
with MEIS1 to facilitate HOX-mediated transcription and oncogenesis, which
are compromised following GSK-3 inhibition in leukemia cells.
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increased their resistance to GSK-3 inhibition (Figure 6E),
consistent with partial bypass of the GSK-3 dependent CREB-
MEIS transcription pathway. Alternatively, FOS knockdown
enhanced sensitivity to GSK-3 inhibition at least 4-fold (Figures
6F and 6G) but did not affect NUP98-HOXA9 immortalized cells,
which are not sensitive toGSK-3 inhibitors. Thus, FOS is a critical
target gene that may integrate the role of GSK-3 in promoting
conditional CREB function to facilitate HOX-mediated transcrip-
tion and leukemic transformation.
DISCUSSION
Acute leukemias induced by MLL chimeric oncoproteins are
among the subset of cancers distinguished by a paradoxical
dependence onGSK-3 kinase activity for sustained proliferation.
In this study, we demonstrate that GSK-3maintains theMLL LSC
transcriptional program by promoting the conditional
association of CREB and its coactivators with MEIS1, a critical
component of the MLL-subordinate HOX/MEIS transcription
complex, which in turn facilitates HOX-mediated transcription.
This mechanism also applies to cells transformed by a variety
of homeodomain proteins, including CDX2, which is highly
expressed in a majority of acute myeloid leukemias, suggesting
that the spectrum of leukemias susceptible to GSK-3 inhibitory
therapies may be much broader than previously anticipated.
Our conclusions are based on the following key observations:
(1) HOXA/MEIS leukemia cells are sensitive to GSK-3 inhibition,
essentially phenocopying MLL leukemia sensitivity both in vitro
and in vivo; (2) CREB along with its coactivators CBP and
TORC physically associates with MEIS1, and modulates HOX/
MEIS transcriptional activity on an authentic promoter; (3)
CREB association with MEIS1 is regulated by phosphorylation
at Ser129 of CREB, a known target of GSK-3; and (4) gene
programs linked with HOX/MEIS as well as CREB are downregu-
lated by GSK-3 inhibition in MLL leukemia cells. Together, these
observations suggest a model (Figure 7) whereby GSK-3 activity
maintains the physical and functional association of CREB with
MEIS to promote critical target gene expression responsible
for HOX-mediated transformation.
In our studies, CREB enhanced the transcriptional activity of
a HOX/MEIS/PBX complex on the Hoxb1 ARE, an authentic
MEIS1 target promoter, and its role in this context appears to
be regulated by GSK-3 phosphorylation. CREB is a multifunc-
tional transcriptional activator that is involved inmany physiolog-
ical pathways under normal and pathologic conditions. CREB
activity is regulated by phosphorylation at Ser133, which is
a target of various kinases depending on the specific signaling
stimulus and cell type. PKA, which is activated by cAMP, is the
major kinase that targets Ser133 in many processes. Ser133
phosphorylation primes CREB for phosphorylation by GSK-3
at Ser129. However, unlike Ser133 phosphorylation, which is
linked with CREB activation, the physiologic consequences of
Ser129 phosphorylation are not well defined, although evidence
suggests that it also is linked with CREB activation (Boer et al.,
2008; Horike et al., 2008; Tyson et al., 2002). We found that
CREB S129A mutation, similar to S133A mutation, antagonized
HOX/MEIS activity and decreased colony-forming abilities of
MLL or HOX/MEIS transformed cells. Consistent with our study,604 Cancer Cell 17, 597–608, June 15, 2010 ª2010 Elsevier Inc.S129 phosphorylation of CREB by GSK-3 is required for recruit-
ment of CBP and subsequent induction of PEPCK-C gene
expression (Horike et al., 2008). Thus, our results support a posi-
tive role of S129 phosphorylation by GSK-3 for CREB activation
of specific transcriptional programs in MLL-transformed cells.
Our studies demonstrate that MEIS1 is a molecular link that
integrates the transcriptional activities of CREB and its coactiva-
tors as a higher order complex whose physical and functional
integrity is dependent on GSK-3 activity. Previous studies have
shown that MEIS1-mediated transcriptional activation is stimu-
lated by PKA and dependent on CBP (Huang et al., 2005).
Further evidence in support of a MEIS-CREB nexus is provided
by the recent demonstration that MEIS1 interacts with TORC
(Goh et al., 2009), a coactivator that also associates with
CREB and modulates its activity (Conkright et al., 2003;
Siu and Jin, 2007). MEIS1 interaction with TORC is also depen-
dent on PKA signaling, which has been shown to regulate the
nuclear translocation of PBX1, an obligate dimerization partner
of MEIS1. Despite the prominent role of PKA in CREB signaling
pathways, treatment with several PKA inhibitors was equally
toxic for leukemia cells transformed by MLL and non-MLL onco-
genes (data not shown), unlike the selective antiproliferative
effects of GSK-3 inhibition. This likely reflects the essential role
of PKA in various physiological processes that mask any
selective role promoting CREB-MEIS interactions in HOX-trans-
formed cells. Thus, it remains to be determined whether GSK-3
may function in concert with PKA to affect a higher-order asso-
ciation of CREB with MEIS1 mediated through TORC and CBP.
The underlying biochemical mechanism for how GSK-3
inhibition or CREB S129 phosphorylation affects MEIS1
association with the TORC/CREB/CBP complex is not entirely
clear. Nevertheless, several conclusions can be drawn from
our study and others. First, the association is likely mediated
through the MEIS1 C terminus because its deletion abrogates
MEIS1 transcriptional activation and association with TORC
(Goh et al., 2009) and CREB (Figures 5I and 5K). Second,
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TORC-enhanced activation by MEIS1 depends on CREB
(Figure 5L), and MEIS1/CREB association depends on TORC
(Figure 5H). Furthermore, CREB S133 and S129 phosphoryla-
tion brings CBP/p300 to MEIS1, and this probably further
stabilizes MEIS1 and CREB association. Loss of S133 or
S129 phosphorylation, which decreases affinity of MEIS1 and
CREB, may involve (1) loss of CBP binding that reduces
CREB and MEIS1 association and (2) conformational changes
of the TORC/CREB complex that alter TORC/CREB binding
(Heinrich et al., 2009) (data not shown). CREB may also directly
modulate MEIS1 and PBX expression (Esparza et al., 2008),
adding to the complexity of their interrelated function. However,
the detailed mechanisms remain to be determined and other
unappreciated factors may also be involved.
Multiple genes are downregulated in MLL-transformed cells
following GSK-3 inhibition. Our studies focused on FOS as a
prototype because it was one of the most differentially
expressed genes in MLL leukemia cells. It encodes a member
of the AP-1 transcription factor family, and as an early response
gene induced by CREB activation, its role in cancer has been
widely studied and shown to enhance the proliferation of trans-
formed cells. In addition to increased proliferation, forced
expression of FOS in our studies rendered MLL leukemia cells
more resistant to GSK-3 inhibition whereas its knockdown
rendered cells more sensitive, suggesting a downstream role
for FOS in mediating the response to GSK-3 inhibitors. FOS
expression levels are likely to be regulated by HOX transcription
complexes as originally suggested by enforced expression of
HOXB4 or HOXC13, which induced FOS expression in fibro-
blasts or epithelial cells, respectively (Krosl and Sauvageau,
2000; Potter et al., 2006). Moreover, FOS levels are decreased
following deletion of MEIS1 (Figure S4C). In our studies, FOS
transcript levels were increased in human leukemia cells
following forced expression of HOXA9 and MEIS1, but not
HOXA9 alone, indicating a regulatory role for the HOX/MEIS
complex. However, reduced FOS levels alone are unlikely to
account for the cell-cycle arrest associatedwith GSK-3 inhibition
because knockdown of FOS to similar low levels achieved by
GSK-3 inhibition did not result in complete cell-cycle arrest.
Consistent with our expression profiling studies, multiple down-
stream genes are likely to mediate the adverse effects of GSK-3
inhibition on MLL leukemia cells.
In conclusion, GSK-3 promotes conditional association of
CREB and its coactivators with MEIS1 to facilitate HOX-medi-
ated transcription and oncogenesis. This provides amechanistic
basis for the paradoxical dependence of MLL-associated leuke-
mias on GSK-3 activity, which critically maintains the MLL LSC
transcriptional program, and suggests a therapeutic approach
to molecularly target HOX-associated transcription. In addition
to MLL leukemias, accumulating evidence indicates that GSK-
3 inhibition blocks proliferation or induces apoptosis in a variety
of cancers including melanoma, myeloma, glioblastoma, and
pancreatic cancer, among others (Korur et al., 2009; Miyashita
et al., 2009; Smalley et al., 2007; Wilson and Baldwin, 2008;
Zhou et al., 2008). It will be of interest to determine how much of
a role, if any, CREB-MEIS interactions contribute to the GSK-3
dependence of these malignancies, which are candidates for
GSK-3 inhibitor therapies.EXPERIMENTAL PROCEDURES
Mice
Mice were maintained on an inbred C57BL/6 background. All experiments on
mice in this study were performed with the approval of and in accordance with
Stanford University’s Administrative Panel on Laboratory Animal Care.
GSK-3 Inhibitors
GSK-3 inhibitors SB216763 (Cat. No. S3442), SB415286 (Cat. No. S3567), AR-
A014418 (Cat. No. A3230), and TDZD-8 (Cat. No. T8325) were purchased from
Sigma and have been described previously (Bhat et al., 2003; Smith et al.,
2001) (Martinez et al., 2002). They were dissolved in dimethyl sulfoxide and
used at the indicated concentrations.
Cell Culture
Human leukemia cell lines were cultured in RPMI 1640 medium supplemented
with 10% fetal calf serum (FCS). Immortalizedmousemyeloid cells or leukemia
cells were cultured in RPMI 1640 supplemented with 20%FCS and 20%WEHI
conditioned medium, or in methylcellulose-containing medium (Methocult
M3231, Stem Cell Technologies) with cytokines, as described previously
(Lavau et al., 1997). 293T and Phoenix cells were cultured in Dulbecco’s modi-
fied Eagle’s medium supplemented with 10% FCS.
Microarray and Bioinformatics Analyses
Human leukemia cell line RS4;11 was cultured in 10 mMSB216763 prior to total
RNA isolation. cDNA was synthesized, fragmented, and hybridized to Affyme-
trix HumanGene (Hu 1.0 ST) microarrays (Affymetrix, Santa Clara, CA) accord-
ing to the manufacturer’s instructions. Microarray data were normalized with
Expression Console software (Affymetrix) with RMA algorithms. Low signals
(below 50) were filtered out using the PreprocessDataset module in GenePat-
tern (http://www.broad.mit.edu/cancer/software/genepattern/). Hierarchical
clustering of microarray samples (Eisen et al., 1998) was based on pairwise
Pearson correlation across preprocessed probe sets. Differentially expressed
genes in SB216763 treated cells versus control were identified using Signifi-
cance Analysis of Microarrays software (Tusher et al., 2001). Genes with a
false-discovery rate below 5% and fold-change over 1.5 were considered
significant. Gene Set Enrichment Analysis (GSEA) (Subramanian et al.,
2005) was used to compare the SB216763-treated data set with gene sets
in Molecular Signatures Database (MSigDB) and gene lists derived from
previous publications. GO analysis was performed using MGI Gene Ontology
Term Finder (http://proto.informatics.jax.org/prototypes/GOTools/web-docs/
MGI_Term_Finder.html).
DNA Constructs and Virus Production
Retroviral constructs encoding MLL-ENL(C), MLL-GAS7, E2A-PBX1, NUP98-
HOXA9, and E2A-HLF were reported previously (Kasper et al., 1999; Smith
et al., 1997; Smith et al., 2002; So et al., 2004). VP16-HD-FKBP was con-
structed by fusing the HOXA9 homeodomain with the VP16 activation domain
and FKBP dimerization domain, respectively. The expression constructs Gal-
MEIS1A (335-390), mutant Gal-MEIS1A(GQWHYM), and FLAG-TORC1/2
were gifts from Mark Featherstone (Nanyang Technological University,
Singapore) (Goh et al., 2009). V5-His-TORC1 was a gift from Dong-Yan Jin
(The University of Hong Kong, Hong Kong) (Siu et al., 2006). HOXA9 reporter
gene was a gift from Xu Cao (University of Alabama, Birmingham, AL) (Wang
et al., 2006). Retroviral vectors encoding c-FOS, CREB and CREB mutants
were constructed using standard cloning techniques. shRNA sequences for
CREB knockdown were designed using pSicoOligomaker v1.5 (http://web.
mit.edu/ccr/labs/jacks/protocols_table.html) (see Supplemental Experimental
Procedures for sequences). shRNA oligos were cloned into pSicoR-puro.
Lentiviruses encoding murine FOS, human CREB, and TORC2 shRNAs were
purchased from Open Biosystems. Retrovirus and lentivirus production was
performed as described previously (Wong et al., 2007).
Transduction of Immortalized Cells or Leukemia cells
Myeloid progenitor transformation assays were performed as described previ-
ously (Lavau et al., 1997). For colony-forming assays, mouse immortalized or
leukemia cells (20,000 cells) were transduced with retrovirus or lentivirus by
spinoculation at 2500 g at 37C for 2 hr. The cells were then incubated inCancer Cell 17, 597–608, June 15, 2010 ª2010 Elsevier Inc. 605
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(Methocult) with cytokines in the absence or presence of indicated concentra-
tions of SB216763. Colonies were counted after 5 days and morphology was
captured with digital photography. The human leukemia cell line RCH-ACV
stably expressing the ecotropic retroviral receptor was transduced with retro-
virus encoding HOXA9 or MEIS1. Cells were selected in the presence of
1 mg/ml puromycin or 250 mg/ml hygromycin.
In Vivo Leukemogenesis Assay
MLL-AF6 immortalized mouse myeloid cells secondarily transduced with
empty vector or CREB were cultured in Methocult and selected with 1 mg/ml
puromycin. Cells (106) harvested frommethylcellulose were transplanted intra-
venously into sublethally irradiated (400 rads) C57BL/6 mice. For lithium treat-
ment, mice transplanted with leukemia cells (50,000 cells) were maintained on
chow (Tekada) containing 0.4% lithium and 0.9%salinewater. Development of
acute leukemia was confirmed by blood smear, peripheral blood leukocyte
counts, and/or histology.
Transcriptional Assay
Transient transcriptional assays were performed in 293T cells as described
previously (Jacobs et al., 1999) using the Top-Flash reporter or reporter
constructs under control of the HOXB1 ARE (Jacobs et al., 1999), Gal-Meis1
(Goh et al., 2009), HOXA9 promoter (Wang et al., 2006), or FOS promoter
(Addgene, plasmid 11983). CMV-LacZ was used as internal control for trans-
fection efficiency.
Immunoprecipitation and Western Blot
Cells were lysed in buffer A (20 mM sodium phosphate [pH 7.0], 250 mMNaCl,
30mMsodium pyrophosphate, 0.1%NP-40, 5mMEDTA, 10mMNaF, 0.1mM
Na3VO4, and 1 mM phenylmethylsulfonyl fluoride) supplemented with
protease inhibitors (Complete, Roche). The lysateswere cleared by centrifuga-
tion at 30,000 g for 10 min at 4C and precleared with anti-immunoglobin G
(IgG) agarose beads, then incubated with anti-FLAG (Sigma) or anti-hemag-
glutinin (HA) (Roche) conjugated agarose beads with rotation at 4C for 4 hr.
The beads were washed five times with buffer A and then washed four times
with cold phosphate-buffered saline. Immunoblotting was performed with
antibodies specific for GSK-3 (Upstate), anti-HA-HRP (Roche), anti-FLAG-
HRP (Sigma), phosph-GSK3 (Cell Signaling), AKT (Cell Signaling), tubulin
(Sigma), CREB and CBP (Santa Cruz Biotechnology), or CDX2 (Santa Cruz
Biotechnology). For coprecipitation of endogenous proteins, cell lysates
prepared from human leukemia cell lines (REH and MV411) were incubated
with CNBr-activated sepharose beads conjugated with anti-MEIS monoclonal
antibody (9.2.7) for 4 hr at 4C. Beads were washed six times with lysis buffer,
and immunoblotting was performed with antisera specific for CREB or MEIS1
(Abcam).
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) assays were performed as previously
described (Yokoyama et al., 2005) using primary antibodies specific for
CREB (sc-186, Santa Cruz Biotechnology) and HA (ab9110, Abcam), or IgG
antibody. Immunocomplexes were precipitated using protein G beads (Dyna-
beads, Invitrogen). Quantitative real-time PCR was performed on the precipi-
tated DNA using primers flanking the consensus CREB site (AGACGTCA) in
the murine FOS gene (mFOS forward: cggcagcctggagcacggagg; mFOS
reverse: cagtgcctgtctcttccatcc). The relative values to input were determined
using SYBR green (Applied Biosystems).
Quantitative RT-PCR
Total RNA was isolated using Trizol (Invitrogen) from cells growing in log
phase, and converted to cDNA using Superscriptase III (Invitrogen). Real-
time PCR was performed with TaqMan probes (Applied Biosystems) using
b-ACTIN as an internal control.
ACCESSION NUMBERS
Microarray raw data are available for download at Gene Expression Omnibus
(http://ncbi.nlm.nih.gov/geo) accession number GSE 19736.606 Cancer Cell 17, 597–608, June 15, 2010 ª2010 Elsevier Inc.SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, two tables, and Supple-
mental Experimental Procedures and can be found with this article online
at doi:10.1016/j.ccr.2010.04.024.ACKNOWLEDGMENTS
We thank M. Ambrus and C. Nicolas for technical assistance, members of the
Cleary lab for helpful discussions, and K. Sakamoto for comments on the
manuscript. F.F. was supported by a fellowship from the American-Italian
Cancer Foundation and an ASH Fellow Scholar Award in basic research.
C.J.M. was supported by PHS grant T32 CA09151 awarded by the National
Cancer Institute, DHHS. We acknowledge support from the Children’s Health
Initiative of the Packard Foundation, PHS grant CA116606, the Leukemia and
Lymphoma Society, the Williams Lawrence Foundation, and a Developmental
Research Award from the Stanford Cancer Center.
Received: December 19, 2009
Revised: February 23, 2010
Accepted: April 16, 2010
Published: June 14, 2010REFERENCES
Abate-Shen, C. (2002). Deregulated homeobox gene expression in cancer:
Cause or consequence? Nat. Rev. Cancer 2, 777–785.
Bhat, R., Xue, Y., Berg, S., Hellberg, S., Ormo¨, M., Nilsson, Y., Radesa¨ter, A.C.,
Jerning, E., Markgren, P.O., Borgega˚rd, T., et al. (2003). Structural insights and
biological effects of glycogen synthase kinase 3-specific inhibitor
AR-A014418. J. Biol. Chem. 278, 45937–45945.
Boer, U., Cierny, I., Krause, D., Heinrich, A., Lin, H., Mayr, G., Hiemke, C., and
Knepel, W. (2008). Chronic lithium salt treatment reduces CRE/CREB-directed
gene transcription and reverses its upregulation by chronic psychosocial
stress in transgenic reporter gene mice. Neuropsychopharmacology 33,
2407–2415.
Carlezon, W.A.J., Duman, R.S., and Nestler, E.J. (2005). The many faces of
CREB. Trends Neurosci. 28, 436–445.
Cohen, P., and Goedert, M. (2004). GSK3 inhibitors: Development and thera-
peutic potential. Nat. Rev. Drug Discov. 3, 479–487.
Conkright, M.D., Canettier, I.G., Screaton, R., Guzman, E., Miraglia, L.,
Hogenesch, J.B., and Montminy, M. (2003). TORCs: Transducers of regulated
CREB activity. Mol. Cell 12, 413–423.
Curran, T., and Teich, N.M. (1982). Identification of a 39,000-dalton protein in
cells transformed by the FBJ murine osteosarcoma virus. Virology 116,
221–235.
De Ferrari, G.V., and Inestrosa, N.C. (2000). Wnt signaling function in Alz-
heimer’s disease. Brain Res. Brain Res. Rev. 33, 1–12.
Doble, B.W., and Woodgett, J.R. (2003). GSK-3: Tricks of the trade for a multi-
tasking kinase. J. Cell Sci. 116, 1175–1186.
Dou, Y., and Hess, J.L. (2008). Mechanisms of transcriptional regulation by
MLL and its disruption in acute leukemia. Int. J. Hematol. 87, 10–18.
Eisen, M.B., Spellman, P.T., Brown, P.O., and Botstein, D. (1998). Cluster anal-
ysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci.
USA 95, 14863–14868.
Esparza, S.D., Chang, J., Shankar, D.B., Zhang, B., Nelson, S.F., and
Sakamoto, K.M. (2008). CREB regulates Meis1 expression in normal and
malignant hematopoietic cells. Leukemia 22, 665–667.
Fiol, C.J., Williams, J.S., Chou, C.H., Wang, Q.M., Roach, P.J., and Andrisani,
O.M. (1994). A secondary phosphorylation of CREB341 at Ser129 is required
for the cAMP-mediated control of gene expression. A role for glycogen syn-
thase kinase-3 in the control of gene expression. J. Biol. Chem. 269,
32187–32193.
Cancer Cell
GSK-3 Promotes MEIS1 and CREB InteractionFutreal, P.A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R.,
Rahman, N., and Stratton, M.R. (2004). A census of human cancer genes.
Nat. Rev. Cancer 4, 177–183.
Goh, S.L., Looi, Y., Shen, H., Fang, J., Bodner, C., Houle, M., Ng, A.C., Screa-
ton, R.A., and Featherstone, M. (2009). Transcriptional activation byMEIS1A in
response to protein kinase A signaling requires the transducers of regulated
CREB family of CREB co-activators. J. Biol. Chem. 284, 18904–18912.
Gonzales, M., and Bowden, G.T. (2002). Ultraviolet B (UVB) induction of the
c-fos promoter is mediated by phospho-cAMP response element binding
protein (CREB) binding to CRE and c-fos activator protein 1 site (FAP1) cis
elements. Gene 293, 169–179.
Heinrich, A., Bo¨er, U., Tzvetkov, M., Oetjen, E., and Knepel, W. (2009). Stimu-
lation by lithium of the interaction between the transcription factor CREB and
its co-activator TORC. Biosci. Rep. 29, 77–87.
Hess, J.L., Bittner, C.B., Zeisig, D.T., Bach, C., Fuchs, U., Borkhardt, A.,
Frampton, J., and Slany, R.K. (2006). c-Myb is an essential downstream target
for homeobox-mediated transformation of hematopoietic cells. Blood 108,
297–304.
Horike, N., Sakoda, H., Kushiyama, A., Ono, H., Fujishiro, M., Kamata, H.,
Nishiyama, K., Uchijima, Y., Kurihara, Y., Kurihara, H., and Asano, T. (2008).
AMP-activated protein kinase activation increases phosphorylation of
glycogen synthase kinase 3beta and thereby reduces cAMP-responsive
element transcriptional activity and phosphoenolpyruvate carboxykinase C
gene expression in the liver. J. Biol. Chem. 283, 33902–33910.
Huang, H., Rastegar, M., Bodner, C., Goh, S.L., Rambaldi, I., and Feather-
stone, M. (2005). MEIS C termini harbor transcriptional activation domains
that respond to cell signaling. J. Biol. Chem. 280, 10119–10127.
Jacobs, Y., Schnabel, C.A., and Cleary, M.L. (1999). Trimeric association of
Hox and TALE homeodomain proteins mediates Hoxb2 hindbrain enhancer
activity. Mol. Cell. Biol. 19, 5134–5142.
Kasper, L.H., Brindle, P.K., Schnabel, C.A., Pritchard, C.E., Cleary, M.L., and
van Deursen, J.M. (1999). CREB binding protein interacts with nucleoporin-
specific FG repeats that activate transcription and mediate NUP98-HOXA9
oncogenicity. Mol. Cell. Biol. 19, 764–776.
Korur, S., Huber, R.M., Sivasankaran, B., Petrich, M., Morin, P.J., Hemmings,
B.A., Merlo, A., and Lino, M.M. (2009). GSK3beta regulates differentiation and
growth arrest in glioblastoma. PLoS ONE 4, e7743.
Kroon, E., Krosl, J., Thorsteinsdottir, U., Baban, S., Buchberg, A.M., and
Sauvageau, G. (1998). Hoxa9 transforms primary bone marrow cells through
specific collaboration with Meis1a but not Pbx1b. EMBO J. 17, 3714–3725.
Krosl, J., and Sauvageau, G. (2000). AP-1 complex is effector of Hox-induced
cellular proliferation and transformation. Oncogene 19, 5134–5141.
Lavau, C., Szilvassy, S.J., Slany, R., and Cleary, M.L. (1997). Immortalization
and leukemic transformation of a myelomonocytic precursor by retrovirally
transduced HRX-ENL. EMBO J. 16, 4226–4237.
Liedtke, M., and Cleary, M.L. (2009). Therapeutic targeting of MLL. Blood 113,
6061–6068.
Luo, J. (2009). Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis
and cancer chemotherapy. Cancer Lett. 273, 194–200.
Martin, M., Rehani, K., Jope, R.S., and Michalek, S.M. (2005). Toll-like
receptor-mediated cytokine production is differentially regulated by glycogen
synthase kinase 3. Nat. Immunol. 6, 777–784.
Martinez, A., Alonso, M., Castro, A., Pe´rez, C., and Moreno, F.J. (2002). First
non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors:
Thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer’s
disease. J. Med. Chem. 45, 1292–1299.
Matthews, C.P., Colburn, N.H., and Young, M.R. (2007). AP-1 a target for
cancer prevention. Curr. Cancer Drug Targets 7, 317–324.
Miyashita, K., Kawakami, K., Nakada, M., Mai, W., Shakoori, A., Fujisawa, H.,
Hayashi, Y., Hamada, J., and Minamoto, T. (2009). Potential therapeutic effect
of glycogen synthase kinase 3beta inhibition against human glioblastoma.
Clin. Cancer Res. 15, 887–897.
Owens, B.M., and Hawley, R.G. (2002). HOX and non-HOX homeobox genes
in leukemic hematopoiesis. Stem Cells 20, 364–379.Ozanne, B.W., Spence, H.J., McGarry, L.C., and Hennigan, R.F. (2007). Tran-
scription factors control invasion: AP-1 the first among equals. Oncogene 26,
1–10.
Potter, C.S., Peterson, R.L., Barth, J.L., Pruett, N.D., Jacobs, D.F., Kern, M.J.,
Argraves, W.S., Sundberg, J.P., and Awgulewitsch, A. (2006). Evidence that
the satin hair mutant gene Foxq1 is among multiple and functionally diverse
regulatory targets for Hoxc13 during hair follicle differentiation. J. Biol.
Chem. 281, 29245–29255.
Ramirez, S., Ait-Si-Ali, S., Robin, P., Trouche, D., and Harel-Bellan, A. (1997).
The CREB-binding protein (CBP) cooperates with the serum response factor
for transactivation of the c-fos serum response element. J. Biol. Chem. 272,
31016–31021.
Rawat, V.P., Thoene, S., Naidu, V.M., Arseni, N., Heilmeier, B., Metzeler, K.,
Petropoulos, K., Deshpande, A., Quintanilla-Martinez, L., Bohlander, S.K.,
et al. (2008). Overexpression of CDX2 perturbs HOX gene expression in murine
progenitors depending on its N-terminal domain and is closely correlated with
deregulated HOX gene expression in human acute myeloid leukemia. Blood
111, 309–319.
Riedt, T., Ebinger, M., Salih, H.R., Tomiuk, J., Handgretinger, R., Kanz, L.,
Grunebach, F., and Lengerke, C. (2009). Aberrant expression of the homeobox
gene CDX2 in pediatric acute lymphoblastic leukemia. Blood 113, 4049–4051.
Schnabel, C.A., Jacobs, Y., and Cleary, M.L. (2000). HoxA9-mediated immor-
talization of myeloid progenitors requires functional interactions with TALE
cofactors Pbx and Meis. Oncogene 19, 608–616.
Scholl, C., Bansal, D., Dohner, K., Eiwen, K., Huntly, B.J., Lee, B.H., Rucker,
F.G., Schlenk, R.F., Bullinger, L., Dohner, H., et al. (2007). The homeobox
gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia
and promotes leukemogenesis. J. Clin. Invest. 117, 1037–1048.
Sitwala, K.V., Dandekar, M.N., and Hess, J.L. (2008). HOX proteins and
leukemia. Int. J. Clin. Exp. Pathol. 1, 461–474.
Siu, Y.T., Chin, K.T., Siu, K.L., Yee, W.C.E., Jeang, K.T., and Jin, D.Y. (2006).
TORC1 and TORC2 coactivators are required for tax activation of the human
T-cell leukemia virus type 1 long terminal repeats. J. Virol. 80, 7052–7059.
Siu, Y.T., and Jin, D.Y. (2007). CREB–a real culprit in oncogenesis. FEBS J.
274, 3224–3232.
Smalley, K.S., Contractor, R., Haass, N.K., Kulp, A.N., Atilla-Gokcumen, G.E.,
Williams, D.S., Bregman, H., Flaherty, K.T., Soengas, M.S., Meggers, E., and
Herlyn, M. (2007). An organometallic protein kinase inhibitor pharmacologi-
cally activates p53 and induces apoptosis in human melanoma cells. Cancer
Res. 67, 209–217.
Smith, D.G., Buffet, M., Fenwick, A.E., Haigh, D., Ife, R.J., Saunders, M., Sling-
sby, B.P., Stacey, R., and Ward, R.W. (2001). 3-Anilino-4-arylmaleimides:
Potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg.
Med. Chem. Lett. 12, 635–639.
Smith, K.S., Jacobs, Y., Chang, C.P., and Cleary, M.L. (1997). Chimeric onco-
protein E2a-Pbx1 induces apoptosis of hematopoietic cells by a p53-indepen-
dent mechanism that is suppressed by Bcl-2. Oncogene 14, 2917–2926.
Smith, K.S., Rhee, J.W., and Cleary, M.L. (2002). Transformation of bone
marrow B-cell progenitors by E2a-Hlf requires coexpression of Bcl-2. Mol.
Cell. Biol. 22, 7678–7687.
So, C.W., Karsunky, H., Wong, P., Weissman, I.L., and Cleary, M.L. (2004).
Leukemic transformation of hematopoietic progenitors by MLL-GAS7 in the
absence of Hoxa7 or Hoxa9. Blood 103, 3192–3199.
Somervaille, T.C., Matheny, C.J., Spencer, G.J., Iwasaki, M., Rinn, J.L., Witten,
D.M., Chang, H.Y., Shurtleff, S.A., Downing, J.R., and Cleary, M.L. (2009).
Hierarchical maintenance of MLL myeloid leukemia stem cells employs a tran-
scriptional program shared with embryonic rather than adult stem cells. Cell
Stem Cell 4, 129–140.
Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L.,
Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., andMe-
sirov, J.P. (2005). Gene set enrichment analysis: A knowledge-based
approach for interpreting genome-wide expression profiles. Proc. Natl.
Acad. Sci. USA 102, 15545–15550.Cancer Cell 17, 597–608, June 15, 2010 ª2010 Elsevier Inc. 607
Cancer Cell
GSK-3 Promotes MEIS1 and CREB InteractionSvingen, T., and Tonissen, K.F. (2003). Altered HOX gene expression in human
skin and breast cancer cells. Cancer Biol. Ther. 2, 518–523.
Tusher, V.G., Tibshirani, R., and Chu, G. (2001). Significance analysis of micro-
arrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. USA
98, 5116–5121.
Tyson, D.R., Swarthout, J.T., Jefcoat, S.C., and Partridge, N.C. (2002). PTH
induction of transcriptional activity of the cAMP response element-binding
protein requires the serine 129 site and glycogen synthase kinase-3 activity,
but not casein kinase II sites. Endocrinology 143, 674–682.
Wang, N., Kim, H.G., Cotta, C.V., Wan, M., Tang, Y., Klug, C.A., and Cao, X.
(2006). TGFbeta/BMP inhibits the bone marrow transformation capability of
Hoxa9 by repressing its DNA-binding ability. EMBO J. 25, 1469–1480.
Wang, Z., Smith, K.S., Murphy, M., Piloto, O., Somervaille, T.C., and Cleary,
M.L. (2008). Glycogen synthase kinase 3 in MLL leukaemia maintenance and
targeted therapy. Nature 455, 1205–1209.608 Cancer Cell 17, 597–608, June 15, 2010 ª2010 Elsevier Inc.Wilson, W.R., and Baldwin, A.S. (2008). Maintenance of constitutive IkappaB
kinase activity by glycogen synthase kinase-3alpha/beta in pancreatic cancer.
Cancer Res. 68, 8156–8163.
Wong, P., Iwasaki, M., Somervaille, T.C., So, C.W., and Cleary, M.L. (2007).
Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell
potential. Genes Dev. 21, 2762–2774.
Yokoyama, A., Somervaille, T.C., Smith, K.S., Rozenblatt-Rosen, O., Meyer-
son, M., and Cleary, M.L. (2005). The menin tumor suppressor protein is an
essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 123,
207–218.
Zhou, Y., Uddin, S., Zimmerman, T., Kang, J.A., Ulaszek, J., and Wickrema, A.
(2008). Growth control of multiple myeloma cells through inhibition of glycogen
synthase kinase-3. Leuk. Lymphoma 49, 1945–1953.
